Methods for reducing the incidence of complications in distal arteriovenous fistula formation
https://doi.org/10.24884/0042-4625-2022-181-5-47-51
Abstract
The OBJECTIVE was to improve the results of surgical treatment and to reduce the incidence of postoperative vascular complications in patients after distal radial-cephalic arteriovenous fistula formation using a new method of vascular anastomosis application and cilostazol medication.
MATERIALS AND METHODS. We studied 69 patients. The comparison group included 32 patients who underwent standard treatment with distal radiocephalic fistula formation according to the generally accepted method without additional conservative treatment. The main group consisted of 37 patients in whom the fistula formation was carried out according to the proposed method, and in the postoperative period, cilostazol medication was used at a dosage of 100 mg mg twice a day for more than 2 months.
RESULTS. The main group showed smaller number of vascular complications: 12 (32.4 %) patients versus 15 (46.8 %) patients in the comparison group.
CONCLUSION. The use of the proposed surgical method for arteriovenous fistula formation in combination with the use of cilostazol in the postoperative period leads to a decrease in the incidence of vascular complications, in particular, to a decrease in the frequency of thrombosis and disorders of the arteriovenous fistula formation.
About the Authors
E. P. Krivoshchekov
Samara State Medical University
Russian Federation
Competing Interests:
Russian Federation
Krivoshchekov Evgeny P., Dr. of Sci. (Med.), Professor of the Department of Surgery (Institute of Professional Education)
Samara
Competing Interests:
The authors declare no conflict of interest.
G. S. Alyapyshev
Ulyanovsk Regional clinical Hospital
Russian Federation
Competing Interests:
Russian Federation
Alyapyshev Grigory S., Surgeon
7, III Internatsionala str., Ulyanovsk, 432017
Competing Interests:
The authors declare no conflict of interest.
V. A. Prutskov
Ulyanovsk Regional clinical Hospital
Russian Federation
Competing Interests:
Russian Federation
Prutskov Vladimir A., Surgeon
Ulyanovsk
Competing Interests:
The authors declare no conflict of interest.
References
1. GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: A systematic analysis for the Global Burden of Disease Study 2016 // Lancet. 2017;390(10100):1151–1210. Doi: 10.1016/S0140-6736(17)32152-9.
2. Borota A. G., Grintsov A. G., Kristulenko A. A. et al. Mistakes and risks of forming vascular access for conducting the hemodialysis // Bulletin of emergency and reconstructive medicine. 2012;13(3):331–332. (In Russ.).
3. Pashin S. V. Opyt nalozheniya arterio-venoznykh fistul s tsel’yu provedeniya programmnogo gemodializa // Nauchno-meditsinskii vestnik tsentral’nogo Chernozem’ya. 2007;29:149–15. (In Russ.).
4. Dember L. M., Beck G. J., Allon M. et al. Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial // JAMA. 2008;299(18):2164–2171. Doi: 10.1001/jama.299.18.2164.
5. Hossny A. Brachiobasilic arteriovenous fistula: different surgical techniques and their effects on fistula patency and dialysis-related complications // Journal of vascular surgery. 2003;37:821–826. Doi: 10.1067/mva.2003.181.
6. Lee T. Novel paradigms for dialysis vascular access: downstream vascular biology – is there a final common pathway? // Clin J Am Soc Nephrol. 2013;8(12):2194–2201. Doi: 10.2215/CJN.03490413.
7. Brahmbhatt A., Remuzzi A., Franzoni M., Misra S. The molecular mechanisms of hemodialysis vascular access failure // Kidney Int. 2016; 89(2):303–316. Doi: 10.1016/j.kint.2015.12.019.
8. Begum N., Hockman S., Manganiello V. C. Phosphodiesterase 3A (PDE3A) deletion suppresses proliferation of cultured murine vascular smooth muscle cells (VSMCs) via inhibition of mitogen-activated protein kinase (MAPK) signaling and alterations in critical cell cycle regulatory proteins // J Biol Chem. 2011;286(29):26238–49. Doi: 10.1074/jbc.M110.214155.
9. Asal N. J., Wojciak K. A. Effect of cilostazol in treating diabetes-associated microvascular complications // Endocrine. 2017;56(2):240–244. Doi: 10.1007/s12020-017-1279-4.
10. Tanaka K., Gotoh F., Fukuuchi Y., Amano T., Uematsu D., Kawamura J. et al. Effects of a selective inhibitor of cyclic AMP phosphodiesterase on the pial microcirculation in feline cerebral ischemia // Stroke. 1989; 20(5):668–73. Doi: 10.1161/01.str.20.5.668.
11. Shakur Y., Holst L. S., Landstrom T. R., Movsesian M., Degerman E., Manganiello V. Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family // Prog Nucleic Acid Res Mol Biol. 2001;66:241–277. Doi: 10.1016/s0079-6603(00)66031-2.
12. Chancharoenthana W., Leelahavanichkul A., Taratummarat S., Wong-phom J., Tiranathanagul K., Eiam-Ong S. Cilostazol attenuates intimal hyperplasia in a mouse model of chronic kidney disease // PLos One. 2017;12(12):e0187872. Doi: 10.1371/journal.pone.0187872.
13. Heinen Y., Stegemann E., Sansone R., Benedens K., Wagstaff R., Balzer J. et al. Local association between endothelial dysfunction and intimal hyperplasia: relevance in peripheral artery disease // J Am Heart Assoc. 2015;4(2):e001472. Doi: 10.1161/JAHA.114.001472.
14. Chitalia N., Ross L., Krishnamoorthy M., Kapustin A., Shanahan C. M., Kaski J. C. et al. Neointimal hyperplasia and calcification in medium sized arteries in adult patients with chronic kidney disease // Semin Dial. 2015;28:E35–40. Doi: 10.1111/sdi.12335.
Supplementary files
Review
For citations:
Krivoshchekov E.P., Alyapyshev G.S., Prutskov V.A. Methods for reducing the incidence of complications in distal arteriovenous fistula formation. Grekov's Bulletin of Surgery. 2022;181(5):47-51. (In Russ.) https://doi.org/10.24884/0042-4625-2022-181-5-47-51
Views:
294
Email this article 